Niagen Biosciences (NAGE) is a company focused on dietary supplements and ingredient raw materials built around nicotinamide riboside, an NAD+ (nicotinamide adenine dinucleotide) precursor that supports cellular energy coenzymes. The flagship brand Tru Niagen generated $24.2 million in revenue, accounting for the bulk of total net revenue, and direct sales through the company's own website grew 23% year over year, demonstrating the strength of the consumer channel. A gross margin of 64.8% indicates that the product mix and channel mix remain favorable.

Although profit scale shrank, the company remained in the black in Q2, with cash inflow from operating activities of roughly $1.6 million in the first half. On top of a cash position of $66.7 million at quarter-end, the company repurchased $2.8 million worth of common stock during the quarter. Over the same period, it launched the Niagen Plus telehealth platform and NV4168, an oral candidate targeting a rare genetic disease and aging-related conditions, sketching out a roadmap for evolving from a nutrition-supplement-centric business into a multi-asset longevity company.

Revenue came in below both the market estimate and the prior-year comparison. Net revenue on the financial statements was $29.785 million, down roughly 4.3% from $31.117 million a year earlier. The bottom line weakened more sharply. Operating income of $700,000 was about one-fifth of the $3.185 million posted in the prior-year period, while total net income of $963,000 marked a steep drop from $3.609 million a year earlier. Basic and diluted EPS also fell from $0.05 and $0.04, respectively, a year ago to $0.01 each.

Rising SG&A added to the pressure. Selling and marketing expenses climbed from $8.207 million a year earlier to $10.13 million, and total operating expenses of $18.614 million were higher year over year. Adjusted EBITDA came in at $3.037 million, down from $5.049 million in the prior-year period. The company said the ingredients business could weaken versus the prior year due to intensified competition, and noted that it would increase investment across commercial, research, and general administrative functions, pushing operating expenses higher.

Management characterized the quarter as a period in which the foundation for long-term growth drivers was laid. CEO Rob Fried emphasized that while maintaining Tru Niagen's category leadership, the company is evolving from a nutrition-supplement business into a multi-asset longevity company through telehealth and pharmaceutical programs. The tone was that the consumer products business is the engine funding the remaining strategic investments, and that the company aims to invest across multiple growth opportunities while preserving the business's cash flow.

The full-year guidance was broken down by segment. E-commerce is expected to grow 10–15% YoY in 2026, while the remaining consumer businesses are expected to meet prior expectations. By contrast, the ingredients business could fall short of the prior year due to a more challenging competitive environment at certain partners, and meaningful contributions from Niagen Plus and the new skincare partnership were pushed out to 2027. With 2026 explicitly designated a year of strategic investment and the guidance built on rising costs, the market's attention will center on the balance between the "growth story" and "near-term profitability."

The post-close response was measured. Despite the profit and the new-business announcements, revenue fell short of estimates, operating profit and net income declined sharply versus the prior year, and the company acknowledged higher costs and ingredients-business weakness for the full year, all of which appeared to weigh on sentiment. As a small-cap name with a market cap of roughly {{MARKET_CAP}} and around {{EMPLOYEES}}, the stock can see outsized price swings on earnings and guidance changes.

The strategic pivot (into telehealth and pharmaceuticals) has yet to be validated by the numbers, and in the near term, consumer-business growth and cost control will be central to how the market reads the stock. In the immediate aftermarket session, the flow was dominated by disappointment-driven selling.